![Jan van den Bossche](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jan van den Bossche
Directeur/Membre du Conseil chez
Immunic AG
Profil
Jan Van den Bossche - Partner
Jan Van den Bossche joined Andera Partners in 2022 as a Partner in the Life Sciences Team.
Prior to joining Andera, Jan was a partner at Fund+, a Belgium based fund investing in the Life Sciences sector.
His career started with Degroof Petercam where he was Sell side Analyst for the Life Sciences sector.
Jan graduated from KULeuven in 2000 as a Master in Applied Economics.
Besides a native Dutch speaker, Jan is also fluent in English and French.
Postes actifs de Jan van den Bossche
| Sociétés | Poste | Début |
|---|---|---|
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Directeur/Membre du Conseil | - |
Indigo Diabetes NV
 Indigo Diabetes NV Medical SpecialtiesHealth Technology Develops medical device for measuring glucose in diabetic patients | Directeur/Membre du Conseil | 27/07/2020 |
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners invests in companies located in France. The firm focuses on a broad range of sectors and industries. It provides debt financing through mezzanine, growth capital but also financing for later stage, LBO, MBO and buyout. The firm seeks for minority or majority stakes and also makes co-investments. | Private Equity Investor | 01/07/2022 |
Anciens postes connus de Jan van den Bossche
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNIC, INC. | Directeur/Membre du Conseil | 05/07/2022 |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Directeur/Membre du Conseil | 01/07/2022 |
OCTIMET Oncology NV
 OCTIMET Oncology NV BiotechnologyHealth Technology Develops discovery stage molecules by employing innovative patient selection | Directeur/Membre du Conseil | 01/07/2022 |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops drugs for antibiotics and first-in-class therapeutics | Directeur/Membre du Conseil | 01/07/2022 |
TargED Biopharmaceuticals BV
 TargED Biopharmaceuticals BV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops biological drugs to improve treatment of thrombosis | Directeur/Membre du Conseil | 01/07/2022 |
Formation de Jan van den Bossche
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
24
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
DSM BV
 DSM BV Chemicals: SpecialtyProcess Industries Manufactures animal and human nutrition & health products | Process Industries |
Vital Therapies, Inc.
 Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotherapeutic company focused on developing a cell-based therapy | Health Technology |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners invests in companies located in France. The firm focuses on a broad range of sectors and industries. It provides debt financing through mezzanine, growth capital but also financing for later stage, LBO, MBO and buyout. The firm seeks for minority or majority stakes and also makes co-investments. | Finance |
Katholieke Universiteit Leuven
 Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Petercam SA (Broker)
 Petercam SA (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Fund+
 Fund+ Investment ManagersFinance Fund+ invests in companies located in Europe primarily in Belgium. The firm focuses on the life sciences primarily active in therapeutics, as well as companies developing diagnostics and medical devices.. It participates in early stage capital requirements with an investment of EUR 5 - 15 million. The firm acquires minority interest and takes a seat on the board of directors. It also makes co-investments and subsequent financing. | Finance |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Health Technology |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Health Technology |
Indigo Diabetes NV
Indigo Diabetes NV Medical SpecialtiesHealth Technology Develops medical device for measuring glucose in diabetic patients | Health Technology |
OCTIMET Oncology NV
OCTIMET Oncology NV BiotechnologyHealth Technology Develops discovery stage molecules by employing innovative patient selection | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops drugs for antibiotics and first-in-class therapeutics | Health Technology |
Immunic, Inc.
 Immunic, Inc. Pharmaceuticals: MajorHealth Technology Develops oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases | Health Technology |
TargED Biopharmaceuticals BV
TargED Biopharmaceuticals BV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops biological drugs to improve treatment of thrombosis | Health Technology |
Choisissez Zonebourse 
